Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03767738 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe
A Phase 4 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 65
- Enrollment target
NCT03767738: Completed Phase 4 study, sponsored by Regeneron Pharmaceuticals.
NCT03767738 is a Phase 4 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 65 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03767738, a Phase 4 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 65 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine if the pre-filled syringe (PFS) supports successful preparation and accurate administration of an aflibercept injection. The secondary objective of the study is to assess ocular safety in the study eye.
Primary Outcome
Participants received a single dose of study drug, administered in the selected study eye with the PFS by a retina specialist. Physician assessed successful aflibercept preparation and administration with the PFS.
Interventions
- DRUG Intravitreal Aflibercept Injection (IAI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2018-12-19 |
| Est. Completion | 2020-08-19 |
| Phase | Phase 4 |
What the finished NCT03767738 record still lists
NCT03767738 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which Intravitreal Aflibercept Injection (IAI) is the first listed.
NCT03767738 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03767738 about?
NCT03767738 is a clinical study titled "Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe". The primary objective of the study is to determine if the pre-filled syringe (PFS) supports successful preparation and accurate administration of an aflibercept injection. The secondary objective of the study is to assess ocular safety in the study eye.
What is the current status of trial NCT03767738?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2018-12-19. Estimated completion is 2020-08-19.
What interventions are being tested in trial NCT03767738?
The interventions under investigation include: Intravitreal Aflibercept Injection (IAI) (DRUG).
Who is sponsoring clinical trial NCT03767738?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03767738's enrollment target sits among peer trials
65 1091st of 2000 higher than 903 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI